Quarterly ResultAug 13, 2026, 04:20 PM
MariMed Q2 Revenue $41.9M; Net Loss $(3.6)M
AI Summary
MariMed Inc. reported a 6.1% increase in Q2 2026 revenue to $41.9 million, with year-to-date revenue reaching $81.4 million, up 5.2%. However, the company's net loss widened to $(3.6) million for the quarter and $(7.3) million for the six months ended June 30, 2026, primarily due to higher income tax provisions and interest expenses. Operating cash flow significantly improved to $3.2 million for the six-month period. The company also restructured its Series B convertible preferred stock and extended a note receivable.
Key Highlights
- Q2 2026 revenue increased 6.1% to $41.9 million from $39.5 million year-over-year.
- Six-month 2026 revenue rose 5.2% to $81.4 million from $77.4 million year-over-year.
- Q2 2026 net loss widened to $(3.6) million, compared to a net loss of $(1.4) million in Q2 2025.
- Six-month 2026 net loss was $(7.3) million, up from $(6.9) million in the prior year.
- Net cash provided by operating activities for six months increased 99.2% to $3.2 million.
- Cash and equivalents decreased to $8.4 million at June 30, 2026 from $8.9 million.
- Total liabilities increased to $147.1 million from $137.8 million at year-end 2025.
- Restructured Series B convertible preferred stock, exchanging $7.1 million for notes payable.
Price Impact
More from MRMD